Thursday, 12 November 2026European Markets
ExploreSearch
ViaNews EU

Central Bank Policy

2 articles

ECB Faces March 19 Policy Test as 92,000 Jobs Lost, Oil Surges 36%

ECB Faces March 19 Policy Test as 92,000 Jobs Lost, Oil Surges 36%

The European Central Bank meets March 19 amid conflicting signals: February job losses hit 92,000 while oil prices jumped 36% on Iran conflict. Former Fed official Loretta Mester says central banks need 'convincing evidence' of inflation retreat before cutting rates, even as labor markets weaken.

ViaNews Editorial Team (Europe)•
Fed Signals More Rate Cuts as ECB Holds Firm, Widening Atlantic Monetary Divide

Fed Signals More Rate Cuts as ECB Holds Firm, Widening Atlantic Monetary Divide

Chicago Fed President Alan Goolsbee said interest rates can drop further in 2026 if inflation moderates, contrasting with the ECB's cautious stance. The divergence pressures the euro as US markets rally on dovish Fed signals while European policymakers maintain tighter conditions. Contactless payments in Finland jumped 23% to €8.4 billion in Q2 2025 as payment infrastructure evolves.

ViaNews Editorial Team (Europe)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com